ALLR - CIK 0001860657
The table below shows Allarity Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.82M | -$17.35M | -$12.74M | -$16.82M | -$14.89M | -$7.25M |
| Capital expenditure | $8.00K | $298.00K | $0.00 | $18.00K | - | $3.00K |
| Investing cash flow | -$8.00K | -$298.00K | $0.00 | $791.00K | $1.00M | -$3.00K |
| Dividends paid | - | - | - | - | - |
Allarity Therapeutics, Inc. reported operating cash flow of -$14.82M for fiscal year 2025. That is up 14.6% from -$17.35M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.25M (FY 2020) to -$14.82M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $3.19M | $0.00 | - | - | - | - |
| Financing cash flow | $10.65M | $36.79M | $10.99M | -$1.31M | $33.82M | $6.03M |